Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Encochleated Amphotericin B (MAT2203) for Antifungal Prophylaxis in AML/ALL
NCT03187691Phase 2Withdrawn
- Sponsor
- Matinas BioPharma
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 2, open-label trial of MAT2203 in invasive fungal infection (IFI) (3 arms), sponsored by Matinas BioPharma. Primary endpoint: Incidence of treatment emergent adverse events at 35 days. Planned start Aug 2019; status: withdrawn.
02
Drugs
MAT2203
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT03187691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187691.